Practical expirience of nimulid and CONDROnova® administration by District specialists and rheumatologists of Moscow

Abstract

Objective. To assess efficacy and safety of nimulid and CONDROnova according to data of District rheumatologists of Moscow Material and methods. 216 adult outpatients (115 with osteoarthritis, 39 with rheumatoid arthritis, 22 with ankylosing spondylitis, 12 with gout, 8 with reactive arthritis, 2 with psoriatic arthritis and 18 with mixed pathology) were included. Nimulid (nimesulid) 200-300 mg/day and CONDROnova (250 mg of glucosamin sulfate and 200 mg of chondroitin sulfate) 2-6 capsules/day were administered as monotherapy or in combination. Quantitative assessment of clinical and laboratory parameters at different stages of therapy was performed. Frequency and spectrum of adverse events in pts with concomitant diseases were analyzed. Results. Nimulid provided fast analgetic and anti-inflammatory effect, Condronova - analgetic effect (with aftereffect). Effect of combination therapy was more rapid. Adverse events frequency in pts with concomitant diseases receiving nimulid and CONDROnova in abovementioned doses was low. Conclusion. Isolated and combined administration of nimulid and CONDROnova in pts with rheumatic diseases is highly effective and safe.

Keywords

• condronova®
• combination therapy
• osteoarthritis
• rheumatoid arthritis
• nimulid